Kachariya Brijesh, Vihar Gadhvi, Amit Gupta, Komal Roopchandani, Nirav Patel
Kachariya Brijesh*,Vihar Gadhvi, Amit Gupta, Komal Roopchandani, Nirav Patel
Department of Pharmaceutics, Mahatma Gandhi College of Pharmaceutical Sciences, ISI-15 (A) RIICO Institutional Area, Sitapura, Tonk Road, Jaipur-302022 (Rajasthan)
Volume - 6,
Issue - 7,
Year - 2013
Monoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic applications. The high demand for these biopharmaceuticals has led to the development of large-scale manufacturing processes, with productivity improvements being mainly achieved by optimization of bioreactor systems. However, more recently, the early steps of production, previous to bioreactor culture, have been presented as alternative areas where productivity enhancements can be achieved. Selection of the most suitable clones is also a critical step that can be improved, by including variables other than the expression level, which is still the common practice. Furthermore, strategies of cell engineering, although still mostly based on trial-and-error experimentation and not in standard protocols, hold great interest to improve cell growth and productivity, as well as product quality in the future. Monoclonal antibodies can be designed that have customized affinityand specificity against drugs of abuse,in vivo pharmacokineticcharacteristics can be tailored to suit specific clinicalapplications (eg, long-acting for relapse prevention, or short-acting for overdose). Passive immunization with antibodies against drugs of abuse has several advantages over active immunization, but because large doses of monoclonal antibodies may be needed for each patient, efficient antibody production technology is essential.
Cite this article:
Kachariya Brijesh, Vihar Gadhvi, Amit Gupta, Komal Roopchandani, Nirav Patel. A Review: Production of Monoclonal Antibody. Research J. Pharm. and Tech 6(7): July 2013; Page 701-705.